BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma (ATYR)aTyr PharmaConference / presentation

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.

Related news

TLSATiziana Life Sciences2026-05-28 11:00 EST

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

XFORX4 Pharmaceuticals2026-05-27 11:00 EST

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

EQEquillium, Inc.2026-05-28 20:05 EST

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

ACRSAclaris Therapeutics2026-05-28 12:30 EST

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

ATYRaTyr Pharma2026-08-07 20:01 EST

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

ATYRaTyr Pharma2026-07-15 12:00 EST

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Stock data

Close
0.50 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States